Literature DB >> 16913197

Clinical approach to patients with neuropathic pain.

Mark Stillman1.   

Abstract

At long last, advances have been made in the field of neuropathic pain treatment, in large part due to a better understanding of the mechanisms underlying this type of pain. New antidepressants and anticonvulsants with novel mechanisms of action have spearheaded the way, and studies have finally shown that opioids are effective for treating chronic and breakthrough pain.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16913197     DOI： 10.3949/ccjm.73.8.726

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  10 in total

1.  Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.

Authors:  Gregor Bender; James Gosset; Jeff Florian; Keith Tan; Mark Field; Scott Marshall; Joost DeJongh; Robert Bies; Meindert Danhof
Journal:  Pharm Res       Date:  2009-08-11       Impact factor: 4.200

2.  Psychologic and biologic factors associated with fatigue in patients with persistent radiculopathy.

Authors:  Angela Starkweather
Journal:  Pain Manag Nurs       Date:  2010-12-30       Impact factor: 1.929

Review 3.  Chemotherapy-induced peripheral neuropathy.

Authors:  Bushra Malik; Mark Stillman
Journal:  Curr Pain Headache Rep       Date:  2008-06

Review 4.  Chemotherapy-induced peripheral neuropathy.

Authors:  Bushra Malik; Mark Stillman
Journal:  Curr Neurol Neurosci Rep       Date:  2008-01       Impact factor: 5.081

5.  A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.

Authors:  Jennifer S Gewandter; Supriya G Mohile; Charles E Heckler; Julie L Ryan; Jeffrey J Kirshner; Patrick J Flynn; Judith O Hopkins; Gary R Morrow
Journal:  Support Care Cancer       Date:  2014-02-16       Impact factor: 3.603

6.  Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research.

Authors:  Michelle C Janelsins; Karen M Mustian; Luke J Peppone; Lisa K Sprod; Michelle Shayne; Supriya Mohile; Kavita Chandwani; Jennifer S Gewandter; Gary R Morrow
Journal:  J Cancer Sci Ther       Date:  2011-09-29

7.  Tolerability of NGX-4010, a capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain.

Authors:  Lynn R Webster; John F Peppin; Frederick T Murphy; Jeffrey K Tobias; Geertrui F Vanhove
Journal:  J Pain Res       Date:  2012-01-20       Impact factor: 3.133

8.  Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia.

Authors:  Lynn R Webster; Margarita Nunez; Marvin D Tark; Edwin D Dunteman; Biao Lu; Jeffrey K Tobias; Geertrui F Vanhove
Journal:  BMC Anesthesiol       Date:  2011-12-19       Impact factor: 2.217

9.  The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis.

Authors:  Till Wagner; Chris Poole; Andrea Roth-Daniek
Journal:  Pain Med       Date:  2013-05-24       Impact factor: 3.750

10.  Treatment of neuropathic pain with the capsaicin 8% patch: is pretreatment with lidocaine necessary?

Authors:  Kai-Uwe Kern; Walburga Nowack; Chris Poole
Journal:  Pain Pract       Date:  2013-12-01       Impact factor: 3.183
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.